• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate.

作者信息

Nahata M C, Powell D A

出版信息

Clin Pharmacol Ther. 1981 Sep;30(3):368-72. doi: 10.1038/clpt.1981.174.

DOI:10.1038/clpt.1981.174
PMID:7273601
Abstract

Bioavailability of chloramphenicol and kinetics of chloramphenicol succinate and chloramphenicol were studied in 12 patients. Chloramphenicol succinate, 25 mg/kg, was injected intravenously every 6 hr over 0.5 to 1 hr. Both the drug and the prodrug were analyzed by high-pressure liquid chromatography. Bioabailability of chlorampenicol ranged from 0.55 to 0.92 and total, renal, and nonrenal clearance from 6.81 to 98.22, 2.54 to 26.90, and 3.73 to 87.38 ml/m2/min, while clearances of chloramphenicol succinate ranged from 84.75 to 916.00 28.40 to 312.00, and 26.06 to 760.93 ml/m2/min. Urinary recovery of chloramphenicol was 3% to 25% and that of chloramphenicol succinate was 7% to 45%. Mean apparent volumes of distribution were 0.71 l/kg for chloramphenicol and 2.10 l/kg for chloramphenicol succinate and elimination half-lifes were 4.03 and 2.65 hr, respecitively. There were relationships between patient age and clearance of both drugs. Incomplete bioavailability of chloramphenicol and the more than 10-fold variability in clearance of both chloramphenicol and chloramphenicol succinate explain the need for individualizing doses to achieve thrapeutic effect and minimize the risk to toxicity.

摘要

相似文献

1
Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate.
Clin Pharmacol Ther. 1981 Sep;30(3):368-72. doi: 10.1038/clpt.1981.174.
2
Pharmacokinetics of chloramphenicol and chloramphenicol succinate in infants and children.氯霉素及琥珀酸氯霉素在婴幼儿和儿童中的药代动力学
J Pediatr. 1981 Feb;98(2):315-20. doi: 10.1016/s0022-3476(81)80670-1.
3
Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients.
Dev Pharmacol Ther. 1983;6(1):23-32. doi: 10.1159/000457274.
4
Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate.氯霉素及琥珀氯霉素的临床药代动力学
Clin Pharmacokinet. 1984 May-Jun;9(3):222-38. doi: 10.2165/00003088-198409030-00004.
5
Relative bioavailability of intravenous chloramphenicol succinate and oral chloramphenicol palmitate in infants and children.
J Pediatr. 1981 Dec;99(6):963-7. doi: 10.1016/s0022-3476(81)80034-0.
6
Chloramphenicol sodium succinate kinetics in critically ill patients.危重症患者中琥珀氯霉素钠的动力学
Clin Pharmacol Ther. 1980 Jul;28(1):69-77. doi: 10.1038/clpt.1980.133.
7
Chloramphenicol dosage and pharmacokinetics in infants and children.
J Clin Pharmacol. 1983 Feb-Mar;23(2-3):106-12. doi: 10.1002/j.1552-4604.1983.tb02712.x.
8
Chloramphenicol succinate kinetics in infants and young children.
Pediatr Pharmacol (New York). 1982;2(2):93-103.
9
Chloramphenicol serum concentration falls during chloramphenicol succinate dosing.
Clin Pharmacol Ther. 1983 Mar;33(3):308-13. doi: 10.1038/clpt.1983.38.
10
Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses.
J Pharmacokinet Biopharm. 1985 Oct;13(5):467-76. doi: 10.1007/BF01059330.

引用本文的文献

1
Ensuring safe and effective medication use in pediatric patients.确保儿科患者用药安全有效。
J Pediatr Pharmacol Ther. 2014 Jan;19(1):4-9. doi: 10.5863/1551-6776-19.1.4.
2
Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.儿科(≤5岁)中葡萄糖醛酸化药物清除率的预测:一种异速生长方法。
Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):53-9. doi: 10.1007/s13318-014-0178-9. Epub 2014 Feb 12.
3
Interplay between pediatric pharmacy practice and research to influence patient care.儿科药学实践与研究之间的相互作用以影响患者护理。
J Pediatr Pharmacol Ther. 2010 Apr;15(2):68-71.
4
Pharmacokinetics of anti-infective agents in paediatric patients.抗感染药物在儿科患者中的药代动力学。
Clin Pharmacokinet. 1994 May;26(5):374-95. doi: 10.2165/00003088-199426050-00005.
5
Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function.静脉注射琥珀氯霉素钠在肾功能和肝功能正常的成年患者中的药代动力学。
J Pharmacokinet Biopharm. 1982 Dec;10(6):601-14. doi: 10.1007/BF01062543.
6
Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate.氯霉素及琥珀氯霉素的临床药代动力学
Clin Pharmacokinet. 1984 May-Jun;9(3):222-38. doi: 10.2165/00003088-198409030-00004.
7
Prodrugs. Do they have advantages in clinical practice?前体药物。它们在临床实践中有优势吗?
Drugs. 1985 May;29(5):455-73. doi: 10.2165/00003495-198529050-00002.
8
Clinical pharmacokinetics in infants and children. A reappraisal.婴幼儿临床药代动力学。重新评估。
Clin Pharmacokinet. 1989;17 Suppl 1:29-67. doi: 10.2165/00003088-198900171-00005.
9
Prodrugs.前体药物
Br J Clin Pharmacol. 1989 Nov;28(5):497-507. doi: 10.1111/j.1365-2125.1989.tb03535.x.
10
Prodrugs for the improvement of drug absorption via different routes of administration.用于通过不同给药途径改善药物吸收的前体药物。
Eur J Drug Metab Pharmacokinet. 1990 Apr-Jun;15(2):143-53. doi: 10.1007/BF03190197.